1. Home
  2. BOW vs RCUS Comparison

BOW vs RCUS Comparison

Compare BOW & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOW
  • RCUS
  • Stock Information
  • Founded
  • BOW 2020
  • RCUS 2015
  • Country
  • BOW United States
  • RCUS United States
  • Employees
  • BOW N/A
  • RCUS N/A
  • Industry
  • BOW Property-Casualty Insurers
  • RCUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • BOW Finance
  • RCUS Health Care
  • Exchange
  • BOW Nasdaq
  • RCUS Nasdaq
  • Market Cap
  • BOW 1.1B
  • RCUS 1.2B
  • IPO Year
  • BOW 2024
  • RCUS 2018
  • Fundamental
  • Price
  • BOW $28.13
  • RCUS $12.03
  • Analyst Decision
  • BOW Buy
  • RCUS Buy
  • Analyst Count
  • BOW 6
  • RCUS 8
  • Target Price
  • BOW $38.33
  • RCUS $20.71
  • AVG Volume (30 Days)
  • BOW 286.6K
  • RCUS 711.9K
  • Earning Date
  • BOW 11-04-2025
  • RCUS 11-05-2025
  • Dividend Yield
  • BOW N/A
  • RCUS N/A
  • EPS Growth
  • BOW 41.97
  • RCUS N/A
  • EPS
  • BOW 1.47
  • RCUS N/A
  • Revenue
  • BOW $492,071,000.00
  • RCUS $262,000,000.00
  • Revenue This Year
  • BOW $19.49
  • RCUS N/A
  • Revenue Next Year
  • BOW $21.79
  • RCUS N/A
  • P/E Ratio
  • BOW $19.05
  • RCUS N/A
  • Revenue Growth
  • BOW 41.21
  • RCUS 6.07
  • 52 Week Low
  • BOW $27.07
  • RCUS $6.50
  • 52 Week High
  • BOW $42.29
  • RCUS $18.98
  • Technical
  • Relative Strength Index (RSI)
  • BOW 31.47
  • RCUS 66.27
  • Support Level
  • BOW $27.42
  • RCUS $11.30
  • Resistance Level
  • BOW $29.57
  • RCUS $12.05
  • Average True Range (ATR)
  • BOW 0.79
  • RCUS 0.58
  • MACD
  • BOW -0.26
  • RCUS 0.02
  • Stochastic Oscillator
  • BOW 14.68
  • RCUS 81.30

About BOW Bowhead Specialty Holdings Inc. Common Stock

Bowhead Specialty Holdings Inc offers commercial specialty property and casualty insurance products. The company offers underwriting solutions to various businesses across four underwriting divisions, which include Casualty, Professional Liability, Healthcare Liability, and Baleen Specialty. A majority of its revenue is generated from the Casualty division which specializes in general liability coverage, which protects a company against liability arising from bodily injury, personal injury or property damage, for risks in the construction, distribution, heavy manufacturing, real estate, public entity and hospitality segments and also considers underwriting risks in a broader range of industries. Geographically, the company operates in the United States.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Share on Social Networks: